


PHARMACEUTICAL 2022

ATAI Life Sciences N.V. Rank 261 of 475









PHARMACEUTICAL 2022

ATAI Life Sciences N.V. Rank 261 of 475



The relative strengths and weaknesses of ATAI Life Sciences N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATAI Life Sciences N.V. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of ATAI Life Sciences N.V. is the variable Net Income, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 141% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	375,082
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,935
Liabilities, Non-Current	4,097
Other Assets	38,935
Other Compr. Net Income	-7,695
Other Expenses	11,491
Other Liabilities	3,175
Other Net Income	-42,428
Property and Equipment	149
Research and Development	47,956
Revenues	20,376
Selling, General and Administrative Expense	92,745

Output Variable	Value in 1000 USD
Assets	414,166
Liabilities	28,207
Expenses	152,192
Stockholders Equity	385,959
Net Income	-174,244
Comprehensive Net Income	-178,092
Economic Capital Ratio	-135%

